Arbor biotechnologies announces collaboration with ginkgo bioworks to advance the discovery and development of precision gene editors

Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage ginkgo's r&d services to further optimize arbor's novel precision editors arbor's portfolio of novel gene editors has significant therapeutic potential because of their unique protospacer adjacent motifs, varied cut types, smaller editing technology, and high specificity ginkgo's high-throughput mammalian foundry enables companies like arbor to optimize novel gene editors with improved functional characteristics by screening in mammalian cells cambridge, mass. and boston , dec. 12, 2023 /prnewswire/ -- arbor biotechnologies, inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced a collaboration with ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, to leverage ginkgo's comprehensive codebase and automated foundry to jointly optimize arbor's novel precision editors.
DNA Ratings Summary
DNA Quant Ranking